Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2014
At a glance
- Drugs Vorinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 03 Jul 2012 Actual end date changed from Jun 2011 to Jul 2011 as reported by ClinicalTrials.gov.
- 03 Jul 2012 Actual patient number is 10 according to ClinicalTrials.gov.
- 11 Aug 2011 Actual end date changed from Sep 2011 to Jun 2011 as reported by ClinicalTrials.gov.